That said, the pandemic has hampered initial uptake, which may shorten the time GBT has to establish its dominance before other gene-therapy players ...
https://www.google.com/url?rct=j&sa=t&url=https://www.nasdaq.com/articles/global-blood-therapeutics%253A-can-this-biotech-still-disrupt-the-sickle-cell-disease-space&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNEyYyX_dIQvYj5usvHo9FtlUrXWog
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.